FOR IMMEDIATE RELEASE
August 29, 2024
CONTACT:
NATIONAL CANNABIS ROUNDTABLE STATEMENT ON HEARING SCHEDULED ON CANNABIS RESCHEDULING
Washington, D.C. – The National Cannabis Roundtable (NCR) released the following statement in response to the U.S. Drug Enforcement Administration (DEA) notice published today in the Federal Register setting a hearing date of December 2, 2024, on its proposed rule to reclassify cannabis as a Schedule III substance.
Saphira Galoob, Executive Director of the National Cannabis Roundtable, released the following statement:
“We remain grateful to the federal agencies involved in the rescheduling of cannabis for treating this process with the seriousness it merits. For significant decisions, it is only logical that all pieces of the administrative process are utilized, and a hearing reflects the gravity of change that accompanies reversing decades of misguided federal drug policy. Along with the overwhelming majority of the tens of thousands of individuals and organizations that submitted comments in support of moving cannabis to Schedule III – or off the CSA entirely – we will continue to stand in strong support with the medical and science-driven analyses by multiple federal health agencies, including FDA and NIDA, that asserted what thousands of doctors and millions of patients across the U.S. have long known – that cannabis has currently accepted medical use. And we will continue to stand in strong support of the concurring recommendations by the Secretary of Health and Human Services and the U.S. Attorney General that cannabis be removed from Schedule I and be reclassified as a Schedule III substance under the federal Controlled Substances Act.
“We look forward to the opportunity to participate in a hearing to speak in strong support of these conclusions, as outlined in our public comments on the proposed rulemaking, and to combat the misinformation being put forward by those who continue to ignore the science and data on cannabis.”
The National Cannabis Roundtable is an alliance of cannabis companies, as well as ancillary services and solutions providers, who seek cannabis reform that nurtures the nascent domestic industry, protects consumers, and advances social equity.
###